Abstracts tagged "autoimmune diseases"

Abstract Number: 2574 • ACR Convergence 2023
Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract
Gabriela Martinez Zayas¹, David Karp¹ and Elena Joerns², ¹UT Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a research classification proposed by the European Respiratory Society and American Thoracic Society Task Force for those…
Abstract Number: 0017 • ACR Convergence 2023
Xist Ribonucleoproteins Promote Female Sex-biased Autoimmunity
Diana Dou¹, Yanding Zhao¹, Julia Belk¹, Yang Zhao¹, Kerriann Casey², Derek Chen¹, Rui Li¹, Bingfei Yu¹, Suhas Srinivasan¹, Brian Abe¹, Katerina Kraft¹, Ceke Hellström³, Ronald Sjöberg⁴, Sarah Chang⁵, Allan Feng⁵, Daniel Goldman⁶, Ami Shah⁷, Michelle Petri⁶, Lorinda Chung⁸, David Fiorentino⁹, Emma Lundberg¹⁰, Anton Wutz¹¹, Paul Utz⁵ and Howard Chang¹, ¹Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Department of Dermatology, Stanford University School of Medicine, Stanford, CA, ²Department of Comparative Medicine, Stanford University, Stanford, CA, ³Autoimmunity and Serology Profiling, Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, ⁴Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁵Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ⁸Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁹Department of Dermatology, Stanford University School of Medicine, Menlo Park, CA, ¹⁰Departments of Bioengineering and Pathology, Stanford University, Stanford, CA, ¹¹Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology, ETH Hönggerberg, Zurich, Switzerland
Background/Purpose: Autoimmune diseases disproportionately affect females more than males. The XX sex chromosome complement is strongly associated with susceptibility to autoimmunity. Xist long noncoding RNA…
Abstract Number: 0089 • ACR Convergence 2023
Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases
Daniel Patton, Meghan Maurer, Nadine Morgan, Minh Pham, Daniel Boster, Justin Huard, Cathy Tan, Rachael Fasnacht, Monica Childs, Gleda Hermansky, Alex Chen, Susan Julien, Jennifer Gardell, Cathy McMahan, Courtney Crane and Kristine Swiderek, Mozart Therapeutics, Seattle, WA
Background/Purpose: In healthy individuals, CD8 Treg activation leads to selective elimination of aberrantly activated self-reactive CD4 T cells to maintain immune balance. The CD8 Treg…
Abstract Number: 0220 • ACR Convergence 2023
Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
Faiza Javed, Tony Mangino and Paramarajan Piranavan, University of Kentucky College of Medicine, Lexington, KY
Background/Purpose: The benefits of antiviral therapy in the COVID-19 patients with underlying rheumatic disease with or without immunosuppression are not entirely clear. The goal of…
Abstract Number: 0339 • ACR Convergence 2023
Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort
Naomi Patel¹, Aubree McMahon¹, Grace McMahon¹, Sebastian Perez-Espina¹, Isha Jha¹, Adam Jarvie¹ and John Stone², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Glucocorticoids (GCs) continue to be the cornerstone of therapy for many rheumatic diseases, though long-term exposure to GCs has been linked to dozens of…
Abstract Number: 0583 • ACR Convergence 2023
Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Miho Oyasu¹, Sivani Pandey¹, Maya Leabman¹, Genevive Hernandez¹, Albert Candia¹, Stephen Carroll¹, Bruce Keyt¹, Maya Kotturi¹, Carrie Brodmerkel² and Mary Beth Harler², ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG antibodies (e.g.rituximab) has been used to treat autoimmune (AI) disease for several decades. However, many patients…
Abstract Number: 0825 • ACR Convergence 2023
A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS)
Rachita Pandya¹, Joshua Dan², Julianne Kleitsch¹, Darosa Lim³, Barbara White⁴ and Victoria P. Werth⁵, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴SFJ Pharmaceuticals, Towson, MD, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Current clinical trials in dermatomyositis (DM) are largely focused on muscle improvement, and use the Total Improvement Score (TIS) as the primary efficacy measure.…
Abstract Number: 1016 • ACR Convergence 2023
Cost-related Medication Burden for Patients with and Without Systemic Autoimmune Rheumatic Diseases
Jeong Yee¹, Candace Feldman¹, Emily G. Oakes¹, Jack Ellrodt¹, May Choi², Elizabeth Karlson¹ and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Medication nonadherence is a challenging issue in the management of systemic autoimmune rheumatic diseases (SARDs), leading to poor clinical outcomes. Although it is complex…
Abstract Number: 1143 • ACR Convergence 2023
Nationwide Analysis of Adult-Onset Still’s Disease with and Without Hemophagocytic Lymphohistiocytosis
Faria Sami¹, Michael Manansala², Shilpa Arora¹ and Augustine Manadan², ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Adult-Onset Still's Disease (AOSD) commonly manifests with fever, arthritis, rash, liver dysfunction, lymphadenopathy, and hematologic abnormalities. AOSD is also associated with Hemophagocytic Lymphohistiocytosis (HLH).…
Abstract Number: 1414 • ACR Convergence 2023
Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis
Philip J. Mease¹, Dafna Gladman², Iain McInnes³, Sue Cheng⁴, Stephen Colgan⁵, Yuri Klyachkin⁶, Lichen Teng⁷ and Nehal Mehta⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³University of Glasgow, Glasgow, United Kingdom, ⁴Amgen, Inc., Bradenton, FL, ⁵Amgen, Inc., Halton Hills, ON, Canada, ⁶Amgen, Inc., Lexington, KY, ⁷Amgen, Inc., Thousand Oaks, CA, ⁸George Washington University School of Medicine, Washington, DC
Background/Purpose: The prevalence of cardiometabolic diseases including obesity and diabetes is higher in patients with psoriatic arthritis (PsA) than those without PsA. Apremilast (APR) is…
Abstract Number: 1634 • ACR Convergence 2023
Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
Benjamin A Fisher¹, Xavier Mariette², Athena S Papas³, Thomas Grader-Beck⁴, Hendrika Bootsma⁵, Wan-Fai Ng⁶, Paul Van Daele⁷, Stephanie Finzel⁸, Sergio Elgueta⁹, Josef Hermann¹⁰, Sara McCoy¹¹, Arthur Bookman¹², Monika Sopala¹³, Wen-Lin Luo¹⁴, Cornelia Scheurer¹³ and Wolfgang Hueber¹³, ¹University of Birmingham, Birmingham, United Kingdom, ²Université Paris-Saclay, Le Kremlin-Bicêtre, France, ³Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, ⁴Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands, ⁶NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁷Department of internal medicine, Erasmus MC, Rotterdam, Netherlands, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ⁹Clinical Research Chile SpA, Biomedical Research Centre, Valdivia, Chile, ¹⁰Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ¹¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ¹²Toronto Western Hospital, Toronto, ON, Canada, ¹³Novartis Pharma AG, Basel, Switzerland, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease affecting secretory glands and other organs with no approved systemic treatments. Iscalimab (CFZ533) is a mAb directed…
Abstract Number: 1801 • ACR Convergence 2023
Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study
Ioanna Minopoulou¹, Koray Tascilar², Giulia Corte¹, Melek Yalcin Mutlu¹, Katja Schmidt², Daniela Bohr¹, Fabian Hartmann², Bernhard Manger², Arnd Kleyer³, David Simon¹, Thomas Harrer², Georg Schett⁴ and Filippo Fagni¹, ¹Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen, Erlangen, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) and particularly those treated with B-cell-depleting agents frequently fail to develop humoral responses to SARS-CoV-2 vaccinations and have…
Abstract Number: 1937 • ACR Convergence 2023
Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis
Frank Cai¹, Anisha Paulson¹, Amy Wozniak², Emily Gilbert² and Rochella Ostrowski², ¹Loyola University Medical Center, Oak Park, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: There is currently a lack of a consensus standardized guideline for the treatment of cardiac sarcoidosis (CS) because of its rarity, heterogeneity of disease…
Abstract Number: 2158 • ACR Convergence 2023
Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Mueller⁶, Steven Sambevski⁷ and Wim A Wuyts⁸, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁸Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital capacity (FVC) compared with placebo,…
Abstract Number: 2463 • ACR Convergence 2023
Efficacy and Safety of Car-T-Cell Treatment in Refractory Antisynthetase Syndrome – Data of the First Three Patients
Jule Taubmann¹, Johannes Knitza², Fabian Müller³, Sebastian Boeltz¹, Simon Voelkl⁴, Michael Aigner⁴, Arnd Kleyer⁵, Ioanna Minnopoulou¹, Regina Gary⁴, Sascha kretschmann⁴, Andreas Mackensen⁴ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ³Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Antisynthetase syndrome (ASS) can be very severe affecting the lungs, the skin and the joints next to the muscles. ASS can take a refractory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.